Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2013
03/28/2013WO2012158789A3 Methods and compositions for inhibiting neddylation of proteins
03/28/2013WO2012155066A3 Spiro-oxindole mdm2 antagonists
03/28/2013WO2012151512A3 Bromodomain inhibitors and uses thereof
03/28/2013WO2012061395A3 Cytotoxic agents against cancer cells and uses thereof
03/28/2013WO2010130779A3 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases
03/28/2013WO2008076278A8 Methods of cancer treatment with igf1r inhibitors
03/28/2013US20130079401 Novel use of isothiocyanates for treating cancer
03/28/2013US20130079387 Antisense oligonucleotide modulation of raf gene expression
03/28/2013US20130079337 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
03/28/2013US20130079324 Pyrrolopyrimidine and purine derivatives
03/28/2013US20130079321 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
03/28/2013US20130079317 Methods for treatment of diseases
03/28/2013US20130079288 Differential effects of drugs on transport in a multi-layer 3d spheroid model
03/28/2013US20130078237 Cd27l antigen binding proteins
03/28/2013US20130078210 Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles
03/28/2013CA2858033A1 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
03/28/2013CA2849710A1 Cachexia treatment
03/28/2013CA2849708A1 Romidepsin and 5 - azacitidine for use in treating lymphoma
03/28/2013CA2849702A1 Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same
03/28/2013CA2849562A1 Vegf/dll4 binding agents and uses thereof
03/28/2013CA2849442A1 Compounds useful as inhibitors of choline kinase
03/28/2013CA2849345A1 Substituted imidazopyridazines
03/28/2013CA2849343A1 Use of strigolactones and strigolactone analogs for treating proliferative conditions
03/28/2013CA2849318A1 Cd27l antigen binding proteins
03/28/2013CA2849259A1 Cancer immunotherapy
03/28/2013CA2849189A1 Morpholino substituted urea or carbamate derivatives as mtor inhibitors
03/28/2013CA2849169A1 Pyrazole carboxamides as janus kinase inhibitors
03/28/2013CA2849168A1 Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
03/28/2013CA2849109A1 N-piperidin-4-yl derivatives
03/28/2013CA2849039A1 Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
03/28/2013CA2847797A1 Benzoic acid derivatives as eif4e inhibitors
03/28/2013CA2847540A1 Pyrrolopyrimidine and purine derivatives
03/28/2013CA2847186A1 Compounds useful as inhibitors of choline kinase
03/28/2013CA2845388A1 Beta-lactam compounds for enhancing t cell-mediated immune responses
03/28/2013CA2843211A1 New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
03/27/2013EP2573176A1 Tumour growth inhibitory compounds and methods of their use
03/27/2013EP2573175A2 ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
03/27/2013EP2573121A1 Antibodies that bind il-4 and/or il-13 and their uses
03/27/2013EP2573120A1 Anti-human trop-2 antibody having anti-tumor activity in vivo
03/27/2013EP2573110A2 Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
03/27/2013EP2573109A2 Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
03/27/2013EP2573079A2 Benzimidazole quinolinones and uses thereof
03/27/2013EP2573073A1 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
03/27/2013EP2573072A1 Indenoquinolone compound, preparation method and use thereof
03/27/2013EP2573069A2 Inhibitors of histone deacetylase and prodrugs thereof
03/27/2013EP2572709A1 HSP90 inhibitors for therapeutic treatment
03/27/2013EP2572706A1 Lipid membrane structure with nuclear transferability
03/27/2013EP2572590A1 Aldehyde removing composition
03/27/2013EP2571989A1 Method for reducing expression of downregulated i renal cell carcinoma i malignant gliomas
03/27/2013EP2571987A1 Reagents and methods for treating cancer
03/27/2013EP2571979A1 Bacterial ribonucleic acid cell wall compositions and methods of making and using them
03/27/2013EP2571901A1 Biological materials related to her3
03/27/2013EP2571884A2 Mtor selective kinase inhibitors
03/27/2013EP2571881A1 Pyrrolopyrazine derivatives as syk and jak inhibitors
03/27/2013EP2571878A1 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
03/27/2013EP2571867A1 Novel pyrimidine derivatives
03/27/2013EP2571863A1 Nilotinib salts and crystalline forms thereof
03/27/2013EP2571577A1 Improved immunotherapeutic dosing regimens and combinations thereof
03/27/2013EP2571531A2 Stabilized fibronectin domain compositions, methods and uses
03/27/2013EP2571529A2 Functional, cross-linked nanostructures for tandem optical imaging and therapy
03/27/2013EP2571528A1 Novel self-reactive arms and prodrugs comprising same
03/27/2013EP2571522A2 Cancer treatment
03/27/2013EP2571513A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
03/27/2013EP2571503A2 Compositions and methods for treating neoplasia, inflammatory disease and other disorders
03/27/2013EP2571501A1 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
03/27/2013EP2571361A1 Pyrazolopyrimidine compounds for the treatment of cancer
03/27/2013EP2571358A1 Combination
03/27/2013EP2571352A1 Selective hdac inhibitors
03/27/2013CN1671391B Novel methods and compositions for alleviating pain
03/27/2013CN1370083B Ninovasive genetic immnization, expression products therefrom, and uses thereof
03/27/2013CN103003695A Method for detecting malignant tumor cells
03/27/2013CN103003424A Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation
03/27/2013CN103003309A Superior efficacy of CD37 antibodies in CLL blood samples
03/27/2013CN103003306A Antibodies
03/27/2013CN103003305A 癌症疫苗 Cancer vaccine
03/27/2013CN103003304A Prophylaxis of colorectal and gastrointestinal cancer
03/27/2013CN103003294A Gene fusion targeted therapy
03/27/2013CN103003283A Crystalline forms of kinase inhibitors
03/27/2013CN103003280A Deuterated pyrrolopyrimidine compounds as inhibitors of CDK4/6
03/27/2013CN103003279A Purine compounds selective for Pi3K P110 delta, and methods of use
03/27/2013CN103003275A Benzoquinolone inhibitors of vmat2
03/27/2013CN103003274A Pyrrolopyridine inhibitors of kinases
03/27/2013CN103003273A Pyrazolopyridine kinase inhibitors
03/27/2013CN103003270A Benzofuranone compound and pharmaceutical composition containing same
03/27/2013CN103003269A Substituted heterocyclyl benzyl pyrazoles, and use thereof
03/27/2013CN103003264A Novel pyrimidine derivatives
03/27/2013CN103003262A Nitrogenated aromatic heterocyclic ring derivative
03/27/2013CN103003250A Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
03/27/2013CN103003234A N-hydroxyformamide derivative and pharmaceutical containing same
03/27/2013CN103002923A Stabilized fibronectin domain compositions, methods and uses
03/27/2013CN103002921A Functional, cross-linked nanostructures for tandem optical imaging and therapy
03/27/2013CN103002920A Modified binding proteins inhibiting the VEGF-A receptor interaction
03/27/2013CN103002919A Tumor targeted delivery of immunomodulators by nanoplymers
03/27/2013CN103002916A Novel anti-cmet antibody
03/27/2013CN103002915A Methods and compositions for inhibition of Treg cells
03/27/2013CN103002914A Compositions and methods for inhibiting MMSET
03/27/2013CN103002905A Use of the SPARC microenvironment signature in the treatment of cancer
03/27/2013CN103002904A Anti-angiogenic agent and method of using such agent
03/27/2013CN103002899A Piperazinotriazines as PI3K inhibitors for use in the treatment antiproliferative disorders
03/27/2013CN103002898A 6-(1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-ylthio)-[1,2,4] triazolo [4,3-b] pyridazine as a c-met inhibitor
1 ... 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 ... 2211